III期黑色素瘤辅助治疗引入后4年总生存的人群研究
该荷兰全国回顾性人群研究比较辅助治疗引入前后诊断的III期黑色素瘤患者的4年总生存(OS)。倾向评分匹配后两组各1215例,4年OS率为71.2%对73.8%(HR=0.90,95%CI 0.77-1.04),各亚期均无显著差异;辅助治疗引入后未见显著4年OS获益,需待随机试验OS结果并权衡利弊。
要点
- 匹配后辅助治疗前后4年OS率71.2%对73.8%,HR=0.90(95%CI 0.77-1.04),无显著差异。
- IIIA-D各亚期比较均未见OS显著差异。
- 辅助治疗获益与风险需个体化权衡,等待随机试验OS数据。
核心结论
- III期黑色素瘤辅助治疗引入后,人群层面4年OS未见显著获益。
研究设计与样本
- 荷兰全国回顾性人群研究,纳入2651例III期黑色素瘤患者。
- 按年龄、性别及四个亚期(IIIA-D)进行倾向评分匹配,匹配后两组各1215例。
- 辅助治疗前队列诊断于2015-2017年,辅助治疗后队列诊断于2019-2020年。
- 无事件患者中位随访:辅助治疗前队列89个月,辅助治疗后队列49个月。
主要发现
- 匹配后4年OS率辅助治疗前队列71.2%,辅助治疗后队列73.8%(HR=0.90,95%CI 0.77-1.04)。
- 不同黑色素瘤亚期比较,两组间OS均无显著差异。
临床怎么用
- 对III期黑色素瘤患者,辅助治疗应结合潜在获益与风险谨慎权衡。
- 随机试验OS结果尚未明确前,不宜将辅助治疗视为已证实的人群OS获益措施。
局限性
- 为回顾性人群研究,非随机对照设计。
- 辅助治疗后队列随访时间较短(无事件者中位49个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant systemic therapy for resected stage III melanoma was introduced in clinical practice following the improved recurrence free survival in randomized controlled trials. However, after ten years of follow-up, adjuvant treatment with dabrafenib plus trametinib did not result in a significant improvement in overall survival (OS). Currently, OS data for adjuvant anti-PD1 therapy are still pending. METHODS: In this retrospective nationwide population-based study, the 4-year OS was compared between patients who were diagnosed with stage III melanoma before and after the introduction of adjuvant therapy in the Netherlands. Propensity score matching (PSM) for age, sex, and four melanoma substages (IIIA-D) was applied to ensure comparability between the pre-adjuvant cohort, comprising patients diagnosed in 2015-2017, and the post-adjuvant cohort with patients diagnosed in 2019-2020. RESULTS: A total of 2651 patients with stage III melanoma were included. The median follow-up for patients without an event was 89 months for the pre-adjuvant cohort and 49 months for the post-adjuvant cohort. After PSM, both cohorts consisted of 1215 patients. The 4-year OS rate was comparable between the pre-adjuvant and post-adjuvant adjuvant cohort (71.2 % vs. 73.8 %, HR=0.90, 95 % CI: 0.77-1.04). No significant difference in OS was observed between cohorts for the different substages of melanoma. DISCUSSION: This population-based analysis of patients with stage III melanoma demonstrated no significant 4-year OS benefit after the introduction of adjuvant therapy. Pending the OS results of the randomized trials, the potential benefits and risks of adjuvant therapy should be carefully weighed for patients with stage III melanoma.
引用
- Janssen JC, Schurink AW, Verhoef C, et al. 4-year overall survival after the introduction of adjuvant therapy for patients with stage III melanoma: A population-based study. Eur J Cancer. 2025. PMID: 41475996. doi:10.1016/j.ejca.2025.116202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。